JACC Achieves Highest Impact Factor to Date
The 2023 Impact Factors showcase the strength of the JACC Journals’ portfolio and remains the strongest among the major cardiovascular portfolios of peer reviewed journals
Related Articles
Pathways & Perspectives with Alice Mims, MD – SOHO Insider
Meet Alice Mims, MD, a professor at The Ohio State University and senior medical director of the BeatAML study. Dr. Mims discusses venetoclax’s role in…
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer | NEJM
Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) is a standard therapy for resectable gastric and gastroesophageal junction adenocarcinomas, but recurrence rates remain hig…
I Struggled With Obesity My Whole Life—Until I Went Plant-Based
After decades of obesity and chronic illness, Deena lost 270 pounds and reclaimed her health after going plant-based.
What Is Lipoprotein(a)? Understanding Its Role in Vascular Health and Cholesterol
Knowing your levels and maintaining a healthy heart could keep things in check
Information for Authors: JAAD Case Reports
AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features. The Journal of…
The Global Syndemic of Modifiable Cardiovascular Risk Factors Projected From 2025 to 2050:
AbstractBackgroundCardiovascular diseases (CVDs) are the leading cause of global mortality. Understanding epidemiologic trends in the modifiable risk factors driving CVDs is essential in designing …
Real-World Data Analysis Suggests Crizanlizumab Reduces SCD Acute Care Need | Docwire News
Researchers also measured in the study cohort a very high discontinuation rate for this agent.
FDA, Biotech Company Hash Out Criteria for Primary Vitreoretinal Lymphoma Agent’s NDA Resubmission | Blood Cancers Today
The agent, investigational drug candidate ADX-2191, is a novel intravitreal injection formulation of methotrexate.
A Case of Postural Orthostatic Tachycardia Syndrome in a 20-Year-Old Female Athlete: Review of Ivabradine Guidelines
AbstractBackgroundPostural orthostatic tachycardia syndrome (POTS) is a disorder characterized by orthostatic intolerance, tachycardia, and syncope. Ivabradine, though not Food and Drug Administrat…
JACC: Case Reports
View the JACC: Case Reports landing page, presenting the most recent and relevant articles on cardiovascular case reports.